Table 2.

Subgroup analysis of the pooled HRs with HOXA-AS2 expression in patients with malignancy.

		No. of studies	No. of patients	Pooled HR (95% CI)		Heterogeneity
				Fixed	Random	I2(%)	P-value
Overall survival(OS)		11	684	2.52 (1.87-3.38)	2.54 (1.72-3.76)	32.2	0.142
Cancer type
Digestive system		4	313	2.55 (1.70-3.82)	2.79 (1.67-4.68)	23	0.273
Non-digestive system		7	371	2.48 (1.62-3.81)	2.17 (1.18-3.99)	44.7	0.093
HR estimation method
Indirectly		8	438	2.00 (1.39-2.86)	2.00 (1.38-2.88)	1.5	0.418
Directly		3	246	4.06(2.42-6.79)	3.96 (2.15-7.28)	27.3	0.253
Sample size
≥50		6	522	2.75 (1.95-3.87)	2.94 (1.69-5.09)	51.7	0.066
<50		5	162	1.97 (1.11-3.51)	1.97 (1.11-3.51)	0	0.484
Follow-up time(month)
≥60		8	483	2.25 (1.62-3.13)	2.17 (1.36-3.47)	38.2	0.125
<60		3	201	3.91 (2.03-7.53)	3.91 (2.03-7.53)	0	0.529
Tumor Tissue origins
Mesenchymal tissue		1	27	0.75 (0.16-3.48)	0.75 (0.16-3.48)	–	–
Epithelial tissue		10	657	2.64 (1.95-3.56)	2.72 (1.86-3.96)	26.6	0.199
DiseaseFree Survival (DFS)		2	158	7.19 (3.20-16.17)	7.19 (3.20-16.17)	0	0.812